EGFR-binding molecules and immunoconjugates thereof

US8790649B2 · kind B2 · utility

Assignee

• IMMUNOGEN, INC. · US

Inventors

• Julianto Setiady · Waltham, US
• Peter U. Park · Lexington, US
• Lingyun Rui · Weston, US
• Thomas Chittenden · Sudbury, US
• Gillian Payne · Newton, US

Key dates

• Filing date: Oct 28, 2011
• Grant date: Jul 29, 2014
• Expiry date: Oct 28, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided.